Literature DB >> 16573773

Barrett's esophagus and medications that relax the lower esophageal sphincter.

Douglas A Corley1, Theodore R Levin, Laurel A Habel, Patricia A Buffler.   

Abstract

OBJECTIVES: Medications that may increase gastroesophageal reflux could be risk factors for esophageal adenocarcinoma; however, epidemiologic studies present conflicting results. We evaluated patients with a high-risk condition, Barrett's esophagus, to identify risk factors that may act early in the carcinogenic process.
METHODS: We conducted a nested case-control study within a large integrated health-services organization. Electronic databases were used to identify incident diagnoses of Barrett's esophagus (cases); two controls were matched to each case. Electronic databases provided information on the use of medications that may induce reflux (nitrates, calcium channel blockers, xanthines, benzodiazepines, and beta agonists) and potential confounders. A supplemental mailed questionnaire evaluated additional potential confounders.
RESULTS: We identified 421 cases and selected 842 controls. The association between any medication use and a Barrett's esophagus diagnosis was modified by age; an increased risk was observed only among subjects <70 yr of age (adjusted odds ratio [OR] = 2.6; 95% confidence interval [CI] 1.5-4.6). A Barrett's esophagus diagnosis was associated with asthma medication use (OR 5.8; 95% CI 2.2, 14.9), but not with the other medications studied. Subgroup analyses suggested that medication use was not independently associated with reflux symptoms and that adjustment for asthma symptoms substantially reduced the association between medication use and a Barrett's esophagus diagnosis.
CONCLUSION: The use of medications that may induce reflux was associated with a Barrett's esophagus diagnosis among younger persons. This association was only observed with asthma medications; the analyses suggested the possibility of confounding by indication, whereby reflux may cause both asthma and Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16573773     DOI: 10.1111/j.1572-0241.2006.00539.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

Review 1.  Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus.

Authors:  Justin B Taylor; Joel H Rubenstein
Journal:  Am J Gastroenterol       Date:  2010-05-18       Impact factor: 10.864

Review 2.  Environmental - lifestyle related factors.

Authors:  Sabine Roman; John E Pandolfino
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-12       Impact factor: 3.043

Review 3.  Erosive tooth wear - a review on global prevalence and on its prevalence in risk groups.

Authors:  N Schlueter; B Luka
Journal:  Br Dent J       Date:  2018-03-02       Impact factor: 1.626

Review 4.  Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma.

Authors:  Joel H Rubenstein; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2015-05-07       Impact factor: 22.682

5.  The role of gastroesophageal reflux in exercise-triggered asthma: a randomized controlled trial.

Authors:  Kathryn A Peterson; Wayne M Samuelson; Darin T Ryujin; David C Young; Kristen L Thomas; Kristen Hilden; John C Fang
Journal:  Dig Dis Sci       Date:  2008-08-08       Impact factor: 3.199

Review 6.  Environmental causes of esophageal cancer.

Authors:  Farin Kamangar; Wong-Ho Chow; Christian C Abnet; Sanford M Dawsey
Journal:  Gastroenterol Clin North Am       Date:  2009-03       Impact factor: 3.806

7.  Risk factors for the development of oesophageal adenocarcinoma in Barrett's oesophagus: a UK primary care retrospective nested case-control study.

Authors:  Sc Cooper; S Menon; Pg Nightingale; Nj Trudgill
Journal:  United European Gastroenterol J       Date:  2014-04       Impact factor: 4.623

8.  Medication usage and the risk of neoplasia in patients with Barrett's esophagus.

Authors:  Dang M Nguyen; Hashem B El-Serag; Louise Henderson; Daniel Stein; Achyut Bhattacharyya; Richard E Sampliner
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-10       Impact factor: 11.382

9.  Current status and future perspectives on the etiology of esophageal adenocarcinoma.

Authors:  Aaron P Thrift; Nirmala Pandeya; David C Whiteman
Journal:  Front Oncol       Date:  2012-02-13       Impact factor: 6.244

10.  Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention.

Authors:  Xiaohong Li; Patricia L Blount; Brian J Reid; Thomas L Vaughan
Journal:  BMC Med Inform Decis Mak       Date:  2014-03-06       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.